Elicit Plant
Elicit Plant, a French agribiotechnology company formed in 2017, has developed a proprietary technology platform that increases the physiological resilience of crops while preserving natural resources. With laboratories in the Charente region of France, and a Brazilian branch in Sao Paulo, the firm has developed an innovative biostimulant using phytosterol, a molecule found in plants. The solution naturally boosts plants' metabolism, reducing the need for water and strengthening resistance to water stress. Elicit Plant's products are aimed at the €4 billion global market for biostimulants.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
www.elicit-plant.com
Related News
Strategic partnership for sustainable agriculture: Bayer and Elicit Plant join forces in France for maize cultivation
Elicit Plant accelerates its international expansion in response to climate change and challenges in the agricultural sector
Elicit Plant announces its upcoming US biosolution launch with demonstrated 20% reduction of water consumption in broad acre crops
Elicit Plant announces the appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)
Elicit Plant makes C&EN’s list of '10 Start-Ups to Watch'
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.